EyePoint Pharmaceuticals Inc (FRA:PV3B)
€ 7.932 0.038 (0.48%) Market Cap: 409.05 Mil Enterprise Value: 136.42 Mil PE Ratio: 0 PB Ratio: 1.69 GF Score: 61/100

EyePoint Pharmaceuticals Inc Investor Day Transcript

Jul 18, 2022 / 12:00PM GMT
Release Date Price: €8
Nancy S. Lurker
EyePoint Pharmaceuticals, Inc. - President, CEO & Director

(technical difficulty) started. So I want to welcome everybody here. So if you could take your seats. We're going to try to make sure we stay on time today. So thank you, first and foremost, for coming today. We really appreciate it. We're very excited about where we are with EyePoint Pharmaceuticals. And I appreciate those of you calling in and those of you who took the time to come, particularly on this rainy day in New York City.

We do have forward-looking statements we will be making. So I'm going to encourage you, just go to our website where our SEC statements are.

I do want to just open up first and foremost and say, just remind everybody, this is a very capital-intensive and a risky business. And more important than anything is that we're here for our patients and to ensure that we are providing treatments to them, and in our case, for very serious retinal eye diseases. I try to stress at EyePoint to all of our employees, at the end of end of the day, that's what this is all about. But because it is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot